EUVIMEDEUVIMED entdecken
Open Access

Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity

Huai Leng Pisaniello iD, Samuel L Whittle, Renea V Johnston, Vanessa Glennon, Liesl Grobler, Sheila Cyril, Anneliese D Arno, Rachelle Buchbinder

Cochrane Database of Systematic Reviews · 2025

DOI: 10.1002/14651858.cd015900 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Database of Systematic Reviews, 2025. Verfasst von Huai Leng Pisaniello und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Psoriatic, Arthritis, Rheumatoid. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To investigate the benefits and harms of dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in adults with rheumatoid arthritis or psoriatic arthritis, who have been in sustained remission or low disease activity. This is a common review protocol, outlining the approach for two separate Cochrane reviews for people with rheumatoid arthritis or psoriatic arthritis. Dose reduction or discontinuation of csDMARDs in adults with rheumatoid arthritis, who have been in sustained remission or low disease activity Dose reduction or discontinuation of csDMARDs in adults with psoriatic arthritis, who have been in sustained remission or low disease activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidAdultHumansRandomized Controlled Trials as TopicRemission Induction

Substanzen

Antirheumatic Agents

Autor:innen und Institutionen

  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia.

ORCID-Profile: Huai Leng Pisaniello

Zitieren

APA

Pisaniello, H. L., Whittle, S. L., Johnston, R. V., Glennon, V., Grobler, L., Cyril, S., Arno, A. D., & Buchbinder, R. (2025). Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd015900

Vancouver

Pisaniello HL, Whittle SL, Johnston RV, Glennon V, Grobler L, Cyril S, et al. Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity. Cochrane Database of Systematic Reviews. 2025. doi:10.1002/14651858.cd015900

BibTeX
@article{Pisaniello2025,
  author = {Pisaniello, Huai Leng and Whittle, Samuel L and Johnston, Renea V and Glennon, Vanessa and Grobler, Liesl and Cyril, Sheila and Arno, Anneliese D and Buchbinder, Rachelle},
  title = {Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity},
  journal = {Cochrane Database of Systematic Reviews},
  year = {2025},
  doi = {10.1002/14651858.cd015900}
}
Kostenlos starten →